Quote:
Any kind of relapse activity or disease progression on TYSABRI is extremely uncommon because the drug is so effective.
|
If one believes Biogen's stats stating that the reduction of risk in disease progression is reduced by 68%, then what about the remaining 32% for patients??!! I hardly doubt that 32% qualifies as "extremely uncommon"!
It's comments like this that really irk me about Tysabri or any other medication that big pharma markets.
Harry